October 24th 2024
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for a patient with relapsed/refractory multiple myeloma and relevance of the KarMMa-3 trial for their treatment.
Ruxolitinib Shines in New, Long-Term Myelofibrosis Data
December 6th 2015Data shows ruxolitinib continues to work in patients with advanced myelofibrosis by maintaining spleen size reduction and overall survival improvements over the course of a 5 year study, according to data presented during the 57th Annual Meeting of the American Society of Hematology.
Read More
Daratumumab Shows Rapid and Durable Responses in Patients With Multiple Myeloma
December 6th 2015Daratumumab demonstrated a 31% overall response rate as monotherapy for patients with heavily pretreated multiple myeloma, according to a combined analysis of two pivotal studies presented at the 2015 ASH Annual Meeting.
Read More
Ixazomib, Cyclophosphamide, Dexamethasone Combination Effective in Myeloma
December 5th 2015The triple combination of ixazomib, cyclophosphamide, and dexamethasone, all taken orally, showed encouraging early response rates in elderly patients with newly diagnosed multiple myeloma, according to phase II data presented at the 2015 ASH Annual Meeting.
Read More
Ixazomib Approved for Relapsed Multiple Myeloma by FDA
November 20th 2015A combination of the oral proteasome inhibitor ixazomib (Ninlaro), lenalidomide (Revlimid) and dexamethasone has been approved by the FDA a full 4 months ahead of schedule for patients with multiple myeloma with at least 1 prior surgery.
Read More
FDA Grants Priority Review to Carfilzomib for Relapsed Multiple Myeloma
September 21st 2015Carfilzomib (Kyprolis) in combination with dexamethasone, was recently granted a priority review designation by the FDA for patients who have relapsed multiple myeloma, following prior treatment with at least one therapy.
Read More
Ixazomib Granted Priority Review by the FDA for Multiple Myeloma
September 10th 2015Ixazomib (MLN9708), an oral proteasome inhibitor, was recently granted a priority review designation by the FDA, in combination with lenalidomide and dexamethasone for the treatment of patients who have relapsed and/or refractory multiple myeloma.
Read More
ELOQUENT-2 Study in Patients With Relapsed/Refractory Multiple Myeloma
August 17th 2015Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma.
Watch
Toxicities Associated With Lenalidomide for Multiple Myeloma
August 14th 2015Philip McCarthy, MD, professor of oncology, director, Blood and Marrow Transplant Center, Department of Medicine, Roswell Park Cancer Institute, discusses the toxicities associated with lenalidomide for multiple myeloma in the CALGB 100104 study.
Watch
Lenalidomide vs. Placebo for Multiple Myeloma Patients Following a Single ASCT
August 13th 2015Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).
Watch
Underused Ovarian Cancer Treatment Improves Overall Survival
August 7th 2015Almost 10 years following a study that proved intraperitoneal (IP), or abdominal, chemotherapy, along with intravenous (IV) therapy, may add 16 months or more to the lives of women with ovarian cancer, less than half of these patients at US hospitals receive this type of treatment
Read More
Monoclonal Antibodies for the Treatment of Patients With Multiple Myeloma
July 31st 2015Ravi Vij, MD, associate professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, discusses the monoclonal antibody daratumumab for the treatment of patients with heavily pretreated multiple myeloma.
Watch
Carfilzomib Phase III ENDEAVOR Data Submitted for FDA Approval in Myeloma
July 24th 2015A supplemental new drug application (sNDA) was recently submitted for carfilzomib (Kyprolis) in combination with dexamethasone for patients who have relapsed multiple myeloma, following previous treatment with at least one therapy.
Read More
NY-ESO-1 TCR Produces Positive Results in Patients With Multiple Myeloma
July 22nd 2015Data from a phase I/II single-arm trial of the NY-ESO-1 T-Cell Receptor (TCR) therapy, recently published in Nature Medicine, is the first to show feasibility and antitumor responses in patients who have multiple myeloma.
Read More
Daratumumab for the Treatment of Patients With Multiple Myeloma
July 6th 2015Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses a phase II study examining daratumumab for the treatment of patients with multiple myeloma.
Watch
Combination of Panobinostat and Carfilzomib in Relapsed or Relapsed/Refractory Multiple Myeloma
June 19th 2015Jesus G. Berdeja, MD, director of Myeloma Research, senior investigator, Hematologic Malignancies Principal Investigator, Sarah Cannon Research Institute, discusses a phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma.
Watch
Patient Selection for the Treatment of Myeloma
April 30th 2015Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses patient selection for the treatment of myeloma, especially relapsed myeloma.
Watch
New Collaboration Forms for Immunotherapy Regimens in Hematologic Malignancies
April 27th 2015MedImmune Limited, a subsidiary of AstraZeneca PLC, and Celgene International II Sà rl, a subsidiary of Celgene Corporation, have formed a strategic collaboration for the development and commercialization of AstraZeneca’s anti-programmed cell death-ligand 1 (PD-L1) agent MEDI4736.
Read More
Advances in Relapsed Multiple Myeloma
April 14th 2015Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses advances in the management of relapsed multiple myeloma.
Watch